~Œ¤‹†•¬

ŠúŒÀ“à‚É•¬‹à‚ðÁ”ï‚·‚é•û–@
Ì‘ð—á



’÷Ø
Šz
‘ÎÛ
‰ž•å—ð
Ì‘ð—ð
‰ÈŒ¤”ï
“Á•ÊŒ¤‹†ˆõDC2

‹‹—¿20–œ‰~ x 24‚©ŒŽ
Œ¤‹†”ï150–œ‰~ x 2”N
”ŽŽm‰Û’ö3”N¶ˆÈã
ƒoƒCƒg•s‰Â


ŽáŽèŒ¤‹†(B)

ŠwˆÊŽæ“¾Œã

2010-2011”N“x
2016-2017”N“x
Šî”ÕŒ¤‹†(C)



2018-2020”N“x
2021/4-2024/3
2024/4-2027/3
•¬‹à
“ú–{“œ”A•aŠw‰ï@ŽáŽèŒ¤‹†•¬‹à
3ŒŽ
100–œ‰~ x 2”N
41Ζ¢–žB‘åŠw‰@¶‚à‰ÂB“¯ˆêuÀ‚©‚ç1–¼BYIA‚Æ“¯Žž‰ž•å‰Â


G-7Œ¤‹†ŠJ”­•¬

300–œ‰~

2020/3-2021/4
2023/4-2024/3
2024/4-2025/3
2025/4-2026/3
PRiME

25–œ‰~


2025/4-2026/3
2026/4-2027/3
—é–Ø–œ•½“œ”A•aà’c@ŽáŽèŒ¤‹†’²¸Œ¤‹†•¬ 9/30 200–œ‰~

2023/4-2025/3
—é–Ø–œ•½“œ”A•aà’c@’²¸Œ¤‹†•¬B

250–œ‰~ x 3”N


2025/4-2028/3
“ú–{”ì–žŠw‰ïEƒmƒ{ƒmƒ‹ƒfƒBƒXƒNƒtƒ@[ƒ}Œ¤‹†•¬

100–œ‰~


2024/1-2024/12
¬–ìˆãŠwŒ¤‹†•¬

300–œ‰~


2024/4-2025/3
Front Runner of Future Diabetes Research



2014-2020”N
‹»˜a¶–½‰ÈŠwU‹»à’cŒ¤‹†•¬
100–œ‰~
40Ζ¢–ž

2020”N“x
MSD¶–½‰ÈŠwà’cŒ¤‹†•¬@¶ŠˆKе•a—̈æ@ŽáŽèŒ¤‹†ŽÒ
100–œ‰~ x 2”N 42Έȉº
2021/1-2022/12
“à“¡‹L”O‰ÈŠw§—ã‹àEŒ¤‹†•¬ 4/28 (Šw“à’÷Ø)




Ž“c‹L”OˆãŠw–òŠwU‹»à’c@Œ¤‹†•¬‹à 5/6




ƒAƒXƒeƒ‰ƒX•a‘Ô‘ãŽÓŒ¤‹†‰ïŒ¤‹†•¬ 5/31



‘æˆêŽO‹¤¶–½‰ÈŠwŒ¤‹†U‹»à’c@Œ¤‹†•¬ 6/30 (Šw“à’÷Ø)




ƒx[ƒŠƒ“ƒK[/ƒŠƒŠ[“œ”A•aŒ¤‹†•¬




MSD§ŠwŠñ•t




“ú–{“à•ª”åŠw‰ïŒ¤‹†•¬




“à“¡‹L”O‰ÈŠw§—ã‹àEŽáŽèƒXƒeƒbƒvƒAƒbƒvŒ¤‹†•¬

‰ß‹Ž‚Ì“à“¡‹L”O‰ÈŠw§—ã‹àEŒ¤‹†•¬‚ÌŽó—ÌŽÒ

‘æˆêŽO‹¤§ŠwŠñ•tƒvƒƒOƒ‰ƒ€




“c•ÓŽO•H»–òДޮ‰ïŽÐŒ¤‹†Žx‰‡